株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

免疫性血小板減少症治療薬の世界市場:2019年~2023年

Global Immune Thrombocytopenia Drugs Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 865032
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
免疫性血小板減少症治療薬の世界市場:2019年~2023年 Global Immune Thrombocytopenia Drugs Market 2019-2023
出版日: 2019年05月29日 ページ情報: 英文 136 Pages
概要

免疫性血小板減少症は若い女性によく見られ、そのリスクは関節リウマチ、HIV、肝炎、ループス、抗リン脂質症候群などの疾患を持つ人々の方が高くなっています。これらの病気の罹患率は世界的に高くなっています。例えば、2016年には、米国の100万人を超える人々がHIV感染と診断され、米国の成人のほぼ1%がC型肝炎を患っていました。このような危険因子の発生率の増加は免疫性血小板減少症の罹患率を高めます。これにより治療法の選択肢に対する需要が高まり、それによって世界の免疫性血小板減少症治療薬市場が、予測期間中に5%近くのCAGRで成長する見込みです。

当レポートでは、世界の免疫性血小板減少症治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • TPO-Ras
  • コルチコステロイド
  • IVIG
  • その他
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 特別な規制の指定
  • 意識向上プログラムの増加
  • バイオシミラーの開発

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Amgen Inc.
  • CSL Ltd.
  • Horizon Therapeutics Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Rigel Pharmaceuticals Inc.

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

図表
  • Exhibit 01: Global hematology drugs market
  • Exhibit 02: Segments of global hematology drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: TPO-Ras - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Approved TPO-Ras
  • Exhibit 21: Pipeline of TPO-Ras
  • Exhibit 22: TPO-Ras - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Some of the generic sponsors for corticosteroids
  • Exhibit 25: Corticosteroids - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: IVIGs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Some of the available IVIGs
  • Exhibit 28: Side effects of IVIGs
  • Exhibit 29: Approximate Costs of IVIGs
  • Exhibit 30: IVIGs - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Other drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Off-label drugs for immune thrombocytopenia
  • Exhibit 33: Other drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Market opportunity by product
  • Exhibit 35: Customer landscape
  • Exhibit 36: Market share by geography 2018-2023 (%)
  • Exhibit 37: Geographic comparison
  • Exhibit 38: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in North America
  • Exhibit 41: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in Europe
  • Exhibit 44: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 45: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 46: Top 3 countries in Asia
  • Exhibit 47: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 48: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 49: Top 3 countries in ROW
  • Exhibit 50: Key leading countries
  • Exhibit 51: Market opportunity
  • Exhibit 52: Prevalence of associated risk factors for immune thrombocytopenia
  • Exhibit 53: Drug development pipeline for immune thrombocytopenia
  • Exhibit 54: Side effects associated with available drugs
  • Exhibit 55: Alternative therapies for immune thrombocytopenia
  • Exhibit 56: Impact of drivers and challenges
  • Exhibit 57: Drug designations
  • Exhibit 58: Vendor landscape
  • Exhibit 59: Landscape disruption
  • Exhibit 60: Vendors covered
  • Exhibit 61: Vendor classification
  • Exhibit 62: Market positioning of vendors
  • Exhibit 63: Amgen Inc. - Vendor overview
  • Exhibit 64: Amgen Inc. - Business segments
  • Exhibit 65: Amgen Inc. - Organizational developments
  • Exhibit 66: Amgen Inc. - Geographic focus
  • Exhibit 67: Amgen Inc. - Key offerings
  • Exhibit 68: Amgen Inc. - Key customers
  • Exhibit 69: CSL Ltd. - Vendor overview
  • Exhibit 70: CSL Ltd. - Business segments
  • Exhibit 71: CSL Ltd. - Organizational developments
  • Exhibit 72: CSL Ltd. - Geographic focus
  • Exhibit 73: CSL Ltd. - Segment focus
  • Exhibit 74: CSL Ltd. - Key offerings
  • Exhibit 75: CSL Ltd. - Key customers
  • Exhibit 76: Horizon Therapeutics Plc - Vendor overview
  • Exhibit 77: Horizon Therapeutics Plc - Business segments
  • Exhibit 78: Horizon Therapeutics Plc - Organizational developments
  • Exhibit 79: Horizon Therapeutics Plc - Geographic focus
  • Exhibit 80: Horizon Therapeutics Plc - Segment focus
  • Exhibit 81: Horizon Therapeutics Plc - Key offerings
  • Exhibit 82: Horizon Therapeutics Plc - Key customers
  • Exhibit 83: Merck & Co. Inc. - Vendor overview
  • Exhibit 84: Merck & Co. Inc. - Business segments
  • Exhibit 85: Merck & Co. Inc. - Organizational developments
  • Exhibit 86: Merck & Co. Inc. - Geographic focus
  • Exhibit 87: Merck & Co. Inc. - Segment focus
  • Exhibit 88: Merck & Co. Inc. - Key offerings
  • Exhibit 89: Merck & Co. Inc. - Key customers
  • Exhibit 90: Novartis AG - Vendor overview
  • Exhibit 91: Novartis AG - Business segments
  • Exhibit 92: Novartis AG - Organizational developments
  • Exhibit 93: Novartis AG - Geographic focus
  • Exhibit 94: Novartis AG - Segment focus
  • Exhibit 95: Novartis AG - Key offerings
  • Exhibit 96: Novartis AG - Key customers
  • Exhibit 97: Rigel Pharmaceuticals Inc. - Vendor overview
  • Exhibit 98: Rigel Pharmaceuticals Inc. - Business segments
  • Exhibit 99: Rigel Pharmaceuticals Inc. - Organizational developments
  • Exhibit 100: Rigel Pharmaceuticals Inc. - Key offerings
  • Exhibit 101: Rigel Pharmaceuticals Inc. - Key customers
  • Exhibit 102: Validation techniques employed for market sizing
  • Exhibit 103: Definition of market positioning of vendors
目次
Product Code: IRTNTR31389

About this market

Immune thrombocytopenia is common among young women, and its risk is higher in people with diseases such as rheumatoid arthritis, HIV, hepatitis, lupus, and antiphospholipid syndrome. The prevalence of these diseases is high across the world. For instance, in 2016, over a million people in the US were diagnosed with HIV infection, and nearly 1% of the adults in the US had Hepatitis C. The growing incidences of such risk factors will increase the prevalence of immune thrombocytopenia. This will increase the demand for treatment options, thereby driving the growth of the global immune thrombocytopenia market size at a CAGR of nearly 5% during the forecast period.

Market Overview

Expected approvals for late-stage pipeline molecules

The market is witnessing accelerated growth in the number of molecules in the pipeline for the treatment of immune thrombocytopenia. At present, there are over 5 therapeutics to treat immune thrombocytopenia. These drugs are in the late stages of development and are slated to receive marketing approvals during the forecast period.

Availability of substitutes

The side effects associated with the available drugs for the treatment of immune thrombocytopenia are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global immune thrombocytopenia market size.

For the detailed list of factors that will drive and challenge the growth of the immune thrombocytopenia market size during 2019-2023.

Competitive Landscape

The market appears to be fragmented with several players occupying the market share. Companies such as Amgen Inc. and CSL Ltd. Have intensified the competition. Factors such as the high prevalence of associated risk factors for immune thrombocytopenia and the expected approvals of late-stage pipeline molecules will provide significant growth opportunities for immune thrombocytopenia drug manufacturers. Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc. are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • TPO-Ras - Market size and forecast 2018-2023
  • Corticosteroids - Market size and forecast 2018-2023
  • IVIGs - Market size and forecast 2018-2023
  • Other drugs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Special regulatory designations
  • Increasing number of awareness programs
  • Development of biosimilars

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • CSL Ltd.
  • Horizon Therapeutics Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Rigel Pharmaceuticals Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Back to Top